News & Events Year None20202019201820172016201520142013201220112009 09/30/20 REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II) 09/25/20 REGENXBIO to Participate in Upcoming Investor Conferences 09/09/20 REGENXBIO Announces Dosing of First Patient in Phase II AAVIATE™ Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery 09/02/20 REGENXBIO to Participate in Upcoming Investor Conferences 08/25/20 REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery 08/06/20 REGENXBIO Reports Second Quarter 2020 Financial Results and Operational Highlights 08/04/20 REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
